MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ
1.360
+0.090
+7.09%
After Hours: 1.310 -0.05 -3.68% 19:59 02/06 EST
OPEN
1.280
PREV CLOSE
1.270
HIGH
1.390
LOW
1.270
VOLUME
230.08K
TURNOVER
--
52 WEEK HIGH
2.600
52 WEEK LOW
0.6302
MARKET CAP
173.61M
P/E (TTM)
-11.9718
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TLSA last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at TLSA last week (0119-0123)?
Weekly Report · 01/26 09:39
Tiziana's Intranasal Foralumab Study Results Published In Peer-Reviewed Journal
NASDAQ · 01/21 09:41
Tiziana Life Sciences’ Intranasal Foralumab MS Study Published in Leading Neurology Journal
TipRanks · 01/20 16:48
Tiziana Life Sciences announces publication of intranasal foralumab results
TipRanks · 01/20 16:20
Tiziana Life Sciences Announces All Participants Demonstrated Stabilization Of Expanded Disability Status Scale Scores In Intranasal Foralumab Trial, 60% Showed Fatigue Improvement
Benzinga · 01/20 16:20
Tiziana Life Sciences Publishes Positive Clinical Results for Intranasal Foralumab in Progressive MS
Reuters · 01/20 16:15
TIZIANA LIFE SCIENCES ANNOUNCES THE PEER-REVIEWED PUBLICATION OF CLINICAL STUDY RESULTS FOR INTRANASAL FORALUMAB
Reuters · 01/20 16:15
More
About TLSA
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).

Webull offers Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ: TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.